Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11662516 | 1.00 | GRIK1 (0.62) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL8515594 | 1.00 | GRIK1 (0.62) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL11546520 | 0.83 | GRIK1 (0.65) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL11546522 | 0.83 | GRIK1 (0.65) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL4556870 | 0.82 | GRIK1 (0.69) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL7168755 | 0.82 | GRIK1 (0.48) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL4556871 | 0.82 | GRIK1 (0.69) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL7276287 | 0.80 | GRIK1 (0.47) | GRIK1GRIK2ALDH1A1TDP1GRIA2 | |
| SCHEMBL19483414 | 0.80 | GRIK1 (0.41) | GRIK1GRIK2ALDH1A1TDP1CA2 | |
| SCHEMBL7276283 | 0.80 | GRIK1 (0.47) | GRIK1GRIK2ALDH1A1TDP1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448757-B2 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | PROCTER & GAMBLE (US) | 2015-04-08 | — | — | EP | claimed |
| EP-1448757-B1 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | PROCTER & GAMBLE (US) | 2012-05-30 | — | — | EP | claimed |
| CN-103025747-A | Process for olefin polymerisation using group 4 metallocene as catalysts | BOREALIS AG | 2013-04-03 | — | — | CN | disclosed |
| CN-102985434-A | Catalyst and process for preparing same | BOREALIS AG | 2013-03-20 | — | — | CN | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-6013792-A | INTERSTITIAL COLLAGENASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIOSTEOPOROSIS AGENTS | SYNTEX (U.S.A.), INC. (US) | 2000-01-11 | — | — | US | disclosed |
| CN-1044249-C | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5773428-A | BONE DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0712403-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004735-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| US-4772325-A | CONTROLLED RELEASE, BORON TRIFLUORIDE COMPLEX WITH LEWIS BASE | KERR MANUFACTURING COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0079940-A4 | FLUORINE CONTAINING DENTAL MATERIALS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1985-07-01 | — | — | EP | disclosed |
| EP-0079940-A1 | FLUORINE CONTAINING DENTAL MATERIALS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-06-01 | — | — | EP | disclosed |
| WO-1982004259-A1 | FLUORINE CONTAINING DENTAL MATERIALS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-12-09 | — | — | WO | disclosed |
| US-4143020-A | COPOLYMERS OF SULFONIC ACID MONOMERS | ROHM AND HAAS COMPANY (US) | 1979-03-06 | — | — | US | disclosed |
| US-4131736-A | Polymers of sulfonic acid monomers | ROHM AND HAAS COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | GRIK1 2088/4885GRIK2 3792/4885ALDH1A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.